GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cambridge Nutritional Sciences CNSL.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

1.55p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in GBP, from our data supplier.

FY2026

Revenue

£7.0m

FY2017FY2026

Net income

−£5.8m

FY2017FY2026

Free cash flow

−£1.4m

FY2017FY2026

Shareholders' equity

£5.7m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue£7.0m£8.3m£9.8m£7.5m£8.5m£6.8m£9.8m£8.8m£8.3m£14.2m
Gross profit£4.3m£5.0m£6.0m£3.2m£4.7m£4.0m£6.3m£5.6m£5.5m£9.2m
Research and development£134,000£433,000£343,000£274,000£343,000£133,000£37,631£23,623£145,456£199,906
Operating income−£1.0m−£640,000−£535,000−£2.8m−£582,000−£488,000−£8.0m−£271,343−£1.4m£694,760
Net income−£5.8m£1.6m−£328,000−£3.9m−£11.3m−£2.1m−£6.8m£974,253−£7.3m£713,261
Diluted earnings per share-0.020.01-0.00-0.02-0.05-0.01-0.040.01-0.060.01

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets£7.4m£13.8m£13.9m£14.4m£17.8m£29.5m£18.8m£23.5m£22.9m£25.8m
Cash and short-term investments£2.6m£4.9m£5.4m£5.1m£1.6m£5.8m——£115,719£737,331
Total liabilities£1.8m£2.4m£4.2m£4.5m£6.0m£6.2m£5.2m£5.3m£5.8m£4.3m
Debt£125,000£349,000£148,000£74,000£370,000£452,000£2.6m£921,760£882,879£862,768
Shareholders' equity£5.7m£11.4m£9.7m£10.0m£11.8m£23.4m£13.6m£18.2m£17.1m£21.5m
Shares outstanding238m238m238m238m225m182m163m129m126m115m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−£1.1m£82,999£607,000−£3.2m−£3.2m−£2.4m£547,607£368,819−£828,497£2.0m
Capital spending−£253,000−£224,999−£59,000−£153,000−£1.5m−£2.8m−£2.2m−£2.7m−£3.3m−£2.7m
Free cash flow−£1.4m−£142,000£548,000−£3.3m−£4.7m−£5.2m−£1.6m−£2.3m−£4.1m−£649,013

Latest quarters

By quarter end

Mar 2026Sept 2025Mar 2025Sept 2024Mar 2024Sept 2023Mar 2023Sept 2022
Revenue£3.1m£3.9m£4.2m£4.1m£4.8m£4.9m£4.1m£3.4m
Gross profit£1.9m£2.4m£2.5m£2.5m£2.7m£2.9m£1.5m£1.6m
Operating income−£654,000−£393,000−£497,000−£178,000−£176,000−£443,000−£2.1m−£650,000
Net income−£5.4m−£397,000£1.8m−£196,000£370,000−£698,000−£1.8m−£2.1m
Diluted earnings per share-0.02-0.000.01-0.000.00-0.00-0.01-0.01
Cash from operations————£1.0m—−£1.0m−£1.0m
Total assets£7.4m£12.7m£13.8m£13.5m£13.9m£13.8m£14.4m£17.1m
Cash and short-term investments£2.6m£3.6m£4.9m£4.5m£5.4m£4.4m£5.1m£2.7m
Debt£100,000£162,000£223,000£76,000£123,000£134,000£55,000£100,000
Shareholders' equity£5.7m£11.1m£11.4m£9.5m£9.7m£9.3m£10.0m£11.8m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.6%0.5%-5.8%
Operating income-27.8%16.4%—
Net income14.7%22.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin60.6%56.7%56.8%60.9%
Operating margin-11.0%-15.3%-12.6%-14.2%
Net margin-27.8%-25.9%-45.6%-33.1%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-0.63.0-19.9-1.5-0.8-23.6-15.418.8-2.227.1
Price to sales0.50.60.70.81.07.310.72.11.91.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 40-to-1 reverse split · 31 Aug 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.